Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease
- PMID: 16183657
- DOI: 10.1093/hmg/ddi340
Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease
Abstract
In postmortem Huntington's disease brains, mutant htt is present in both nuclear and cytoplasmic compartments. To dissect the impact of nuclear and extranuclear mutant htt on the initiation and progression of disease, we generated a series of transgenic mouse lines in which nuclear localization or nuclear export signal sequences have been placed N-terminal to the htt exon 1 protein carrying 144 glutamines. Our data indicate that the exon 1 mutant protein is present in the nucleus as part of an oligomeric or aggregation complex. Increasing the concentration of the mutant transprotein in the nucleus is sufficient for and dramatically accelerates the onset and progression of behavioral phenotypes. Furthermore, nuclear exon 1 mutant protein is sufficient to induce cytoplasmic neurodegeneration and transcriptional dysregulation. However, our data suggest that cytoplasmic mutant exon 1 htt, if present, contributes to disease progression.
Similar articles
-
Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.Neurobiol Dis. 2006 Feb;21(2):381-91. doi: 10.1016/j.nbd.2005.07.014. Epub 2005 Sep 16. Neurobiol Dis. 2006. PMID: 16150600
-
Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.Hum Mol Genet. 2005 Dec 15;14(24):3823-35. doi: 10.1093/hmg/ddi407. Epub 2005 Nov 8. Hum Mol Genet. 2005. PMID: 16278236
-
Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice.Hum Mol Genet. 2004 Aug 1;13(15):1599-610. doi: 10.1093/hmg/ddh175. Epub 2004 Jun 9. Hum Mol Genet. 2004. PMID: 15190011
-
Huntingtin and its role in neuronal degeneration.Neuroscientist. 2004 Oct;10(5):467-75. doi: 10.1177/1073858404266777. Neuroscientist. 2004. PMID: 15359012 Review.
-
Selective degeneration in YAC mouse models of Huntington disease.Brain Res Bull. 2007 Apr 30;72(2-3):124-31. doi: 10.1016/j.brainresbull.2006.10.018. Epub 2006 Nov 16. Brain Res Bull. 2007. PMID: 17352936 Review.
Cited by
-
Probing the Huntingtin 1-17 membrane anchor on a phospholipid bilayer by using all-atom simulations.Biophys J. 2015 Mar 10;108(5):1187-98. doi: 10.1016/j.bpj.2015.02.001. Biophys J. 2015. PMID: 25762330 Free PMC article.
-
Cell Type-Specific Transcriptomics Reveals that Mutant Huntingtin Leads to Mitochondrial RNA Release and Neuronal Innate Immune Activation.Neuron. 2020 Sep 9;107(5):891-908.e8. doi: 10.1016/j.neuron.2020.06.021. Epub 2020 Jul 17. Neuron. 2020. PMID: 32681824 Free PMC article.
-
Unusual structures are present in DNA fragments containing super-long Huntingtin CAG repeats.PLoS One. 2011 Feb 11;6(2):e17119. doi: 10.1371/journal.pone.0017119. PLoS One. 2011. PMID: 21347256 Free PMC article.
-
Polyglutamine-rich suppressors of huntingtin toxicity act upstream of Hsp70 and Sti1 in spatial quality control of amyloid-like proteins.PLoS One. 2014 May 14;9(5):e95914. doi: 10.1371/journal.pone.0095914. eCollection 2014. PLoS One. 2014. PMID: 24828240 Free PMC article.
-
Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease.J Biol Chem. 2010 Mar 19;285(12):8808-23. doi: 10.1074/jbc.M109.075028. Epub 2010 Jan 19. J Biol Chem. 2010. PMID: 20086007 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases